rebel Financial rebel Financial
← All Posts

Moderna, Inc.

May 07, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 To elect two Class II director nominees set forth in the proxy statement, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her other respective successor is duly elected and qualified or such directors's earlier death, resignation or removal.
1a Sandra Horning, M.D. ✓ For
1b Abbas Hussain ✓ For
2 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. ✓ For
3 To approve, on a non-binding, advisory basis, the frequency of future non-binding advisory votes to approve the compensation of our named executive officers. 1 Year
4 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026. ✓ For
Attachments
📄
MRNA_10k.pdf 1.8 MB
📄
MRNA_Proxy_Statement.pdf 3.5 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.